var data={"title":"Prothrombin complex concentrate, 4-factor, unactivated, from human plasma: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Prothrombin complex concentrate, 4-factor, unactivated, from human plasma: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/340890?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-patient-drug-information\" class=\"drug drug_patient\">see &quot;Prothrombin complex concentrate, 4-factor, unactivated, from human plasma: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20858539\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Arterial and venous thromboembolic complications:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Patients being treated with vitamin K antagonist therapy have underlying disease states that predispose them to thromboembolic events. Weigh potential benefits of reversing vitamin K antagonist against the potential risks of thromboembolic events, especially in patients with history of a thromboembolic event. Carefully consider resumption of anticoagulation as soon as the risk of thromboembolic events outweighs the risk of acute bleeding.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Both fatal and nonfatal arterial and venous thromboembolic complications have been reported with prothrombin complex concentrate in clinical trials and postmarketing surveillance. Monitor patients receiving prothrombin complex concentrate for signs and symptoms of thromboembolic events.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Prothrombin complex concentrate was not studied in subjects who had a thromboembolic event, myocardial infarction, disseminated intravascular coagulation, cerebral vascular accident, transient ischemic attack, unstable angina pectoris, or severe peripheral vascular disease within the prior 3 months. Prothrombin complex concentrate may not be suitable in patients with thromboembolic events in the prior 3 months.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20858540\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Kcentra</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5541091\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Beriplex P/N;</li>\n      <li>Octaplex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5541095\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Blood Product Derivative;</li>\n      <li>\n        Hemostatic Agent;</li>\n      <li>\n        Prothrombin Complex Concentrate (PCC)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5541713\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: Prothrombin complex concentrate (Human) [(Factors II, VII, IX, X), Protein C, Protein S] contains therapeutic levels of factor VII component</b> and should not be confused with Factor IX complex (Human) [Factors II, IX, X] (Bebulin, Profilnine) which contains low or nontherapeutic levels of factor VII.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Kcentra, Beriplex P/N [Canadian product]: </i></b> <b>Vitamin K antagonist (VKA) reversal in patients with acute major bleeding or need for an urgent surgery/invasive procedure:</b> IV: Individualize dosing based on current pre-dose INR. Dosage is expressed in units of factor IX activity. Administer with vitamin K concurrently. Repeat dosing is not recommended (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pretreatment INR: 2 to &lt;4: Administer 25 units/kg; maximum dose: 2,500 units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pretreatment INR: 4 to 6: Administer 35 units/kg; maximum dose: 3,500 units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pretreatment INR: &gt;6: Administer 50 units/kg; maximum dose: 5,000 units</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Octaplex [Canadian product]:</i></b> <b>Bleeding/perioperative prophylaxis of bleeding during vitamin K antagonist therapy:</b> Individualize dosing based on severity of disorder, extent and location of bleeding, and clinical status of patient. IV: Approximate doses required for normalization of INR (&le;1.2 within 1 hour); dosage is expressed in units of factor IX activity:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pretreatment INR: 2 to 2.5: Administer 22.5 to 32.5 units/kg; maximum dose: 3,000 units (or 120 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pretreatment INR: 2.5 to 3: Administer 32.5 to 40 units/kg; maximum dose: 3,000 units (or 120 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pretreatment INR: 3 to 3.5: Administer 40 to 47.5 units/kg; maximum dose: 3,000 units (or 120 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pretreatment INR: &gt;3.5: Administer &gt;47.5 units/kg; maximum dose: 3,000 units (or 120 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">With the correction of vitamin K antagonist-induced impairment of hemostasis in patients who have been treated concomitantly with an appropriate vitamin K dose, repeat dosing with PCC is usually not necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Life-threatening hemorrhage associated with non-vitamin K antagonist anticoagulation (off-label use):</b> IV: <b>Optimal dosing has not been established. </b>According to the European Heart Rhythm Association, the use of 50 units/kg (with additional 25 units/kg if clinically necessary) is recommended based on very limited evidence in healthy volunteers (EHRA [Heidbuchel 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">\n      <i>Intracranial hemorrhage (ICH) due to various antithrombotic agents according to </i>\n      <i>the Neurocritical Care Society/Society of Critical Care Medicine (NCS/SCCM [Frontera 2016]): </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:2em;\">Oral direct factor Xa inhibitor-mediated (apixaban, edoxaban, rivaroxaban): 50 units/kg if ICH occurred within 3 to 5 terminal half-lives of drug exposure or when liver failure co-exists.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:2em;\">Direct thrombin inhibitor-mediated (argatroban, dabigatran [if idarucizumab unavailable], bivalirudin, desirudin): 50 units/kg if direct thrombin inhibitor was administered within a period of 3 to 5 half-lives prior and there is no evidence of renal failure <b>or</b> there is renal impairment leading to drug exposure beyond 3 to 5 half-lives.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5541712\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">Octaplex [Canadian product]: Adolescents &ge;17 years: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5541714\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20858544\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20858545\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20858546\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kcentra, Beriplex [Canadian product]: In patients weighing &gt;100 kg; do not exceed maximum dose recommended according to pretreatment INR.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Octaplex [Canadian product]: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20960658\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kcentra: ~500 units, ~1000 units [pyrogen free; contains albumin human, antithrombin iii (human), heparin]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25574219\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25484314\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Potency on the vial label is expressed in terms of the Factor IX nominal strength (500 units or 1,000 units). Consult individual vial labels for exact potency within each vial.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Total active ingredient composition of 500 unit vial is:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Factor II: 380 to 800 units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Factor VII: 200 to 500 units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Factor IX: 400 to 620 units (Kcentra) or 500 units (Beriplex P/N)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Factor X: 500 to 1,020 units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Protein C: 420 to 820 units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Protein S: 240 to 680 units</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Total active ingredient composition of 1,000 unit vial is:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Factor II: 760 to 1,600 units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Factor VII: 400 to 1,000 units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Factor IX: 800 to 1,240 units (Kcentra) or 1,000 units (Beriplex P/N)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Factor X: 1,000 to 2,040 units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Protein C: 840 to 1,640 units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Protein S: 480 to 1,360 units</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Octaplex [Canadian product]: <b>Note:</b> Potency on the vial label is expressed in terms of the Factor IX nominal strength (500 units or 1,000 units). Consult individual vial labels for exact potency within each vial.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Total active ingredient composition of 500 unit vial is:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Factor II: 280 to 760 units</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Factor VII: 180 to 480 units</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Factor IX: 500 units</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Factor X: 360 to 600 units</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Protein C: 260 to 620 units</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Proteins S: 240 to 640 units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Total active ingredient composition of 1,000 unit vial is:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Factor II: 560 to 1,520 units</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Factor VII: 360 to 960 units</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Factor IX: 1,000 units</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Factor X: 720 to 1,200 units</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Protein C: 520 to 1,240 units</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Protein S: 480 to 1,280 units</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10076333\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kit, Intravenous [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Beriplex P/N: 500 units, 1000 units [pyrogen free, contains albumin human, heparin; packaged with diluent]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Octaplex: 500 units, 1000 units [contains heparin, polysorbate 80; packaged with diluent]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5541715\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kcentra, Beriplex P/N [Canadian product]: IV: Administer at room temperature at a rate of 0.12 mL/kg/minute (~3 <b>units</b>/kg/minute); do <b>not</b> exceed 8.4 mL/minute (~210 <b>units</b>/minute). Do not allow blood to enter into syringe (fibrin clot formation may occur).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Octaplex [Canadian product]: IV: Administer at a rate of 1 mL/minute initially, followed by 2 to 3 mL/minute. Reduce infusion rate or interrupt infusion if patient&rsquo;s pulse rate increases significantly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5541097\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Bleeding, treatment and prophylaxis:</b> Urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA) (eg, warfarin) therapy in patients with acute major bleeding or a need for an urgent surgery/invasive procedure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49096481\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Life-threatening bleeding associated with non-vitamin K antagonist anticoagulants</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20996439\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The term &ldquo;Prothrombin Complex Concentrate&rdquo; or &ldquo;PCC&rdquo; has been used to describe both Factor IX Complex (Human) [Factors II, IX, X] and Prothrombin Complex Concentrate (Human) [(Factors II, VII, IX, X), Protein C, Protein S]. <b>Prothrombin Complex Concentrate (Human) [(Factors II, VII, IX, X), Protein C, Protein S] (Kcentra, Octaplex) contains therapeutic levels of factor VII component</b> and should not be confused with Factor IX complex (Human) [Factors II, IX, X] (Bebulin, Profilnine) which contains low or nontherapeutic levels of factor VII.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Kcentra vials may contain differing amounts of Factor IX units per vial.  The exact amount of Factor IX units in each vial should be used when calculating and preparing the total dose to be administered.  Overdosage errors have occurred when the dose has been improperly calculated. (ISMP, 2014) </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5541171\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension (5% to 7%), tachycardia (3% to 5%), atrial fibrillation (4%), hypertension (1% to 3%), pulmonary embolism (&le;2%), pulmonary edema (2%), cerebrovascular accident (1% to 2%), arteriovenous fistula site complication (clot, &le;1%), chest pain (1%), deep vein thrombosis (1%), venous thrombosis (calf, 1%; radial vein: &le;1%), thrombosis (microthrombosis of toes, &le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (1% to 8%), insomnia (1% to 5%), intracranial hemorrhage (3%), mental status changes (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypervolemia (1% to 6%), hypokalemia (2% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea and vomiting (4% to 6%), constipation (2%), diarrhea (2%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic and oncologic: Anemia (3% to 6%), prolonged bleeding time (skin laceration, contusion, subcutaneous hematoma, 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum transaminases (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (parvovirus B19 seropositive, 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Burning sensation at injection site (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (4%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pleural effusion (4%), respiratory distress (2% to 4%), rales (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Postmarketing and/or case reports: Angioedema, anxiety, arterial thrombosis, bronchospasm, disseminated intravascular coagulation, flushing, hypersensitivity reaction, myocardial infarction, peripheral ischemia, tachypnea, thromboembolic complications, thrombosis, transient ischemic attacks, urticaria, venous insufficiency, wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5541101\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;\">Kcentra, Beriplex P/N [Canadian product]: Hypersensitivity (ie, anaphylaxis or severe systemic reaction) to prothrombin complex concentrate (PCC) or any component of the formulation including factors II, VII, IX, X, protein C and S, antithrombin III and human albumin; disseminated intravascular coagulation (DIC); known heparin-induced thrombocytopenia (product contains heparin).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Octaplex [Canadian product]: Hypersensitivity to prothrombin complex concentrate (PCC) or any component of the formulation; heparin-induced thrombocytopenia type II or known allergy to heparin (product contains heparin); non-life-threatening bleeding episodes in individuals with recent myocardial infarction, high risk of thrombosis, or angina pectoris; non-life-threatening bleeding episodes in individuals with untreated disseminated intravascular coagulation (DIC) who can be given fresh frozen plasma (FFP); coagulation disorders due to chronic liver disease or liver transplantation; bleeding associated with hepatic parenchyme disorders, esophageal varices, or major hepatic surgery; immunoglobulin A (IgA) deficiency, with known antibodies against IgA</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5541102\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Hypersensitivity reaction (eg, angioedema, bronchospasm, dyspnea, flushing, hypotension, nausea/vomiting, pulmonary edema, urticaria, tachycardia, tachypnea) may occur; if serious reaction occurs, discontinue administration and begin appropriate treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolic events: <b>[US Boxed Warning]: Because patients being treated with vitamin K antagonist (VKA) therapy have an underlying risk of or a diagnosed thromboembolic disease state, administration of prothrombin complex concentrate (PCC) may predispose the patient to a thromboembolic complication. Benefits of reversing VKA therapy should be weighed against the potential risk of a thromboembolic event. Resumption of anticoagulation should occur once the risk of thromboembolism outweighs the risk of acute bleeding. Fatal and nonfatal arterial and venous thromboembolic complications and DIC have been reported; closely monitor for thromboembolic events during and after administration. Use has not been evaluated in patients who have experienced a thromboembolic event, MI, DIC, CVA, TIA, unstable angina, or severe peripheral vascular disease within the prior 3 months.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypercoagulopathy: Administration of PCC may exacerbate underlying hypercoagulable states in recipients of vitamin K antagonists.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heparin: Formulations may contain heparin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: <b>Prothrombin complex concentrate (Human) [(Factors II, VII, IX, X), Protein C, Protein S] contains therapeutic levels of factor VII component</b> and should not be confused with Factor IX complex (Human) [Factors II, IX, X] (Bebulin, Profilnine) which contains low or nontherapeutic levels of factor VII.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Coagulation factor deficiency: Hepatic synthesis of the prothrombin complex (Factors II, VII, IX and X) coagulation factors is vitamin K dependent. Severe hepatic dysfunction, inadequate absorption of vitamin K (eg, pancreatic disorders, diarrhea) or vitamin K antagonist therapy or overdose may lead to coagulation factor deficiencies. In patients with an acquired deficiency of the vitamin K dependent coagulation factors, administer PCC only if a rapid correction (eg, emergency surgery, major bleeding) is necessary. If not indicated and caused by Vitamin K antagonist therapy, coagulation factor deficiencies may be managed by reducing or discontinuing therapy of the vitamin K antagonist and/or administration of vitamin K.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49648047\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49648044\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9450&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5541098\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Parvovirus B19 or hepatitis A, which may be present in plasma-derived products, may affect a pregnant woman more seriously than a nonpregnant woman.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20858542\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if prothrombin complex concentrate is present in breast milk. The manufacturer recommends that prothrombin complex concentrate be administered only if clearly needed when treating a breastfeeding woman.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5541717\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">INR (baseline and at 30 minutes post dose); clinical response during and after treatment; signs of thromboembolism</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5541709\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Prothrombin complex concentrate provides an increase in the levels of the vitamin K-dependent coagulation factors (II, VII, IX, and X) with the addition of protein C and protein S. Coagulation factors II, IX, and X are part of the intrinsic coagulation pathway, while factor VII is part of the extrinsic coagulation pathway. In the <i>extrinsic</i> pathway, damaged blood vessels release endothelial tissue factor (TF) which complexes with factor VII to form TF-factor VIIa. Within the <i>intrinsic</i> pathway, factor IX is converted to IXa. Factor IXa (as well as TF-factor VIIa) converts factor X to factor Xa in the final common pathway of coagulation. Factor Xa activates prothrombin (factor II) into thrombin (IIa) which converts fibrinogen into fibrin resulting in clot formation. Proteins C and S are vitamin K-dependent inhibiting enzymes involved in regulating the coagulation process. Protein S serves as a cofactor for protein C which is converted to activated protein C (APC). APC is a serine protease which inactivates factors Va and VIIIa, limiting thrombotic formation. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5541197\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Rapid; significant INR decline within 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: ~6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: Factor II: 71.4 mL/kg; Factor VII: 45 mL/kg; Factor IX: 114.3 mL/kg; Factor X: 55.5 mL/kg; Protein C: 62.2 mL/kg; Protein S: 78.8 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Factor II: 48 to 60 hours; Factor VII: 1.5 to 6 hours; Factor IX: 20 to 24 hours; Factor X: 24 to 48 hours; Protein C: 1.5 to 6 hours; Protein S: 24 to 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Half-lives may be significantly reduced in severe hepatocellular damage, DIC, or extended catabolic metabolism.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21121600\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Kcentra Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $2.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $2.77</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24057156\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Beriplex (IL);</li>\n      <li>Beriplex P/N (AR, AU, BR, DE, ES, GB, NL, SI);</li>\n      <li>Cofact (BE, NL);</li>\n      <li>Confidex (BE, FR);</li>\n      <li>Kcentra (JP);</li>\n      <li>Octaplex (AE, BE, DE, DK, EE, ES, FI, FR, IL, IS, LB, LT, LU, LV, NL, NO, PL, SG, SI, SK, TR, VE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Beriplex P/N (prothrombin complex concentrate human) [product monograph]. Ottawa, Ontario, Canada: CSL Behring Canada Inc; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cartmill M, Dolan G, Byrne JL, et al, &ldquo;Prothrombin Complex Concentrate for Oral Anticoagulant Reversal in Neurosurgical Emergencies,&rdquo; <i>Br J Neurosurg</i>, 2000, 14(5):458-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/11198768/pubmed\" target=\"_blank\" id=\"11198768\">11198768</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care</i>. 2016;24(1):6-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/26714677/pubmed\" target=\"_blank\" id=\"26714677\">26714677</a>]</span><span class=\"doi\">10.1007/s12028-015-0222-x</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):7-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/22315257/pubmed\" target=\"_blank\" id=\"22315257\">22315257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i>. 2015;17(10):1467-1507.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/26324838/pubmed\" target=\"_blank\" id=\"26324838\">26324838</a>]</span><span class=\"doi\">10.1093/europace/euv309</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hemphill JC 3rd, Greenberg SM, Anderson CS, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46(7):2032-2060.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/26022637/pubmed\" target=\"_blank\" id=\"26022637\">26022637</a>]</span><span class=\"doi\">10.1161/STR.0000000000000069.</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practice (ISMP). Misleading Kcentra Label Leads to Dosage Errors. Acute Care ISMP Medication Safety Alert, July 31, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kcentra (prothrombin complex concentrate human) [prescribing information]. Kankakee, IL: CSL Behring; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lubetsky A, Hoffman R, Zimlichman R, et al. Efficacy and Safety of a Prothrombin Complex Concentrate (Octaplex) for Rapid Reversal of Oral Anticoagulation. <i>Thromb Res.</i> 2004;113(6):371-378.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/15226091/pubmed\" target=\"_blank\" id=\"15226091\">15226091</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Makris M, &ldquo;Optimization of the Prothrombin Complex Concentrate Dose for Warfarin Reversal,&rdquo; <i>Thromb Res</i>, 2005, 115(6):451-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/15792674/pubmed\" target=\"_blank\" id=\"15792674\">15792674</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/24589852/pubmed\" target=\"_blank\" id=\"24589852\">24589852</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Octaplex (prothrombin complex concentrate human) [product monograph]. Toronto, Ontario, Canada: Octapharma Canada Inc; August 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pabinger I, Brenner B, Kalina U, et al, &ldquo;Prothrombin Complex Concentrate (Beriplex&reg; P/N) for Emergency Anticoagulation Reversal: A Prospective Multinational Clinical Trial,&rdquo; <i>J Thromb Haemost</i>, 2008, 6(4):622-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/18208533/pubmed\" target=\"_blank\" id=\"18208533\">18208533</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tomaselli GF, Mahaffey KW, Cuker A, et al. 2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. <i>J Am Coll Cardiol</i>. 2017;70(24):3042-3067. doi: 10.1016/j.jacc.2017.09.1085.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/29203195/pubmed\" target=\"_blank\" id=\"29203195\">29203195</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9450 Version 109.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F20858539\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F20858540\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F5541091\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F5541095\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F5541713\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F5541712\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F5541714\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F20858544\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F20858545\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20858546\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F20960658\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F25574219\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F25484314\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F10076333\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F5541715\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F5541097\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F49096481\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F20996439\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F5541171\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F5541101\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F5541102\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F49648047\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F49648044\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5541098\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20858542\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F5541717\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F5541709\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F5541197\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F21121600\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F24057156\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9450|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-patient-drug-information\" class=\"drug drug_patient\">Prothrombin complex concentrate, 4-factor, unactivated, from human plasma: Patient drug information</a></li></ul></div></div>","javascript":null}